Tirzepatide Pharma (formerly Bachem Pharma with no affiliation with Bachem AG)- an innovative CDMO and contract manufacturer for GLP-1 Peptide drug, approved USA manufacturer of GLP-1 Peptide drugs, Tirzepatide injection manufacturing, Semaglutide injectable, GLP-1 oral semaglutide tablets and capsules. It is the leading, innovation-driven company specializing in the development and manufacture of peptides, peptide drugs, and oligonucleotides. The company, with over 30 years of experience and expertise, provides products for research, clinical development, and commercial applications to pharmaceutical and biotechnology companies worldwide, offering a comprehensive range of services. Tirzepatide Pharma operates internationally with headquarters in Switzerland and locations in Europe, the US, and Asia. 

If you require immediate response, please send an email to: cdmo@tirzepatidefirm.com or complete the contact form. Thank you!

 To place an order online please click here 

Admin Offices: 1400 Preston Rd, Plano, TX 75093./Clean-Room Production Site: 802 E Walnut St., Garland, Texas 75040.  Hours of Operation: 8 am-4 pm CST Monday-Friday

Four Locations Serving Texas: Garland. Houston. Dallas. Plano

Tirzepatide Firm (Pharma )is an innovative CDMO and contract manufacturer for GLP-1 Peptide drug, approved USA manufacturer of GLP-1 Peptide drugs, Tirzepatide injection manufacturing, Semaglutide injectable, GLP-1 oral semaglutide tablets and capsules 

The GMP site in Garland, Texas, serves as the clean room center of excellence for the Tirzepatide Pharm Americas organization, specializing in the development of new chemical entities (NCEs). With in-depth knowledge and expertise in chemistry, manufacturing, and controls (CMC), the site is well-positioned to achieve successful commercialization. Together with state-of-the-art equipment and a rapidly growing degree of automation, the Garland site delivers efficient peptide active pharmaceutical ingredient (API) development and manufacturing on a small to medium scale.

The Houston location manufactures commercial API, peptide, new chemical entities (NCEs), and intermediates using state-of-the-art equipment and facilities. Since its acquisition, the site has undergone significant capacity expansion to meet the market demand for peptide products on a medium and large scale. The site also provides custom synthesis for research-grade peptides.

The current management is a trio of former Pfizer bioengineers specializing in the development of new vaccine products, now merging with RapheGenerics as Tirzepatide Pharma to create a better well-being for all. Our mission is to meet consumer needs by offering high-quality products that enhance well-being, research-grade items, and solutions for non-GMP product requirements. We design molecules tailored to your precise specifications, accommodating any scale from milligrams to kilograms and tons. Rely on our expertise to produce complex peptides with various modifications, utilizing advanced synthesis methods and cutting-edge automated production technology. With 30 years of experience, we are excited to embark on this new journey.